| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Cellular Biology, University of Georgia, Athens, GA 30602
Infection with Trypanosoma cruzi results in the development of both type 1 and type 2 patterns of cytokine responses during acute and chronic stages of infection. To investigate the role of Th1 and Th2 subsets of CD4+ T cells in determining the outcome of T. cruzi infection in mice, we have developed T. cruzi clones that express OVA and have used OVA-specific TCR-transgenic T cells to generate OVA-specific Th1 and Th2 cells. BALB/c mice receiving 107 OVA-specific Th1 cells and then challenged with OVA-expressing T. cruzi G-OVA.GPI showed significantly lower parasitemia and increased survival in comparison to mice that received no cells. In contrast, recipients of OVA-specific Th2 cells developed higher parasitemias, exhibited higher tissue parasitism and inflammation, and had higher mortality than recipients of Th1 cells after infection with T. cruzi G-OVA.GPI. Mice receiving a mixture of both Th1 and Th2 OVA-specific cells also were not protected from lethal challenge. The protective effect of the OVA-specific Th1 cells was OVA dependent as shown by the fact that transfer of OVA-specific Th1 or Th2 cells failed to alter the course of infection or disease in mice challenged with wild-type T. cruzi. Immunohistochemical analysis of OVA-specific Th1 and Th2 cells at 4, 15, and 30 days postinfection revealed the persistence and expansion of these cells in mice challenged with T. cruzi G-OVA.GPI but not in mice infected with wild-type T. cruzi. We conclude that transfer of Ag-specific Th1 cells but not Th2 cells protect mice from a lethal infection with T. cruzi.
This article has been cited by other articles:
|
|
 |
|
  D. F. Hoft, C. S. Eickhoff, O. K. Giddings, J. R. C. Vasconcelos, and M. M. Rodrigues Trans-Sialidase Recombinant Protein Mixed with CpG Motif-Containing Oligodeoxynucleotide Induces Protective Mucosal and Systemic Trypanosoma cruzi Immunity Involving CD8+ CTL and B Cell-Mediated Cross-Priming J. Immunol., November 15, 2007; 179(10): 6889 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Reyes, L. I. Terrazas, B. Espinoza, D. Cruz-Robles, V. Soto, I. Rivera-Montoya, L. Gomez-Garcia, H. Snider, A. R. Satoskar, and M. Rodriguez-Sosa Macrophage Migration Inhibitory Factor Contributes to Host Defense against Acute Trypanosoma cruzi Infection. Infect. Immun., June 1, 2006; 74(6): 3170 - 3179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Prickett, P. M. Gray, S. L. Colpitts, P. Scott, P. M. Kaye, and D. F. Smith In vivo recognition of ovalbumin expressed by transgenic leishmania is determined by its subcellular localization. J. Immunol., April 15, 2006; 176(8): 4826 - 4833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bertholet, A. Debrabant, F. Afrin, E. Caler, S. Mendez, K. S. Tabbara, Y. Belkaid, and D. L. Sacks Antigen Requirements for Efficient Priming of CD8+ T Cells by Leishmania major-Infected Dendritic Cells Infect. Immun., October 1, 2005; 73(10): 6620 - 6628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hoft and C. S. Eickhoff Type 1 Immunity Provides Both Optimal Mucosal and Systemic Protection against a Mucosally Invasive, Intracellular Pathogen Infect. Immun., August 1, 2005; 73(8): 4934 - 4940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Gubbels, B. Striepen, N. Shastri, M. Turkoz, and E. A. Robey Class I Major Histocompatibility Complex Presentation of Antigens That Escape from the Parasitophorous Vacuole of Toxoplasma gondii Infect. Immun., February 1, 2005; 73(2): 703 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Martin and R. L. Tarleton Antigen-Specific T Cells Maintain an Effector Memory Phenotype during Persistent Trypanosoma cruzi Infection J. Immunol., February 1, 2005; 174(3): 1594 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lieke, S. E. B. Graefe, U. Klauenberg, B. Fleischer, and T. Jacobs NK Cells Contribute to the Control of Trypanosoma cruzi Infection by Killing Free Parasites by Perforin-Independent Mechanisms Infect. Immun., December 1, 2004; 72(12): 6817 - 6825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pepper, F. Dzierszinski, A. Crawford, C. A. Hunter, and D. Roos Development of a System To Study CD4+-T-Cell Responses to Transgenic Ovalbumin-Expressing Toxoplasma gondii during Toxoplasmosis Infect. Immun., December 1, 2004; 72(12): 7240 - 7246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dumonteil, J. Escobedo-Ortegon, N. Reyes-Rodriguez, A. Arjona-Torres, and M. J. Ramirez-Sierra Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice Infect. Immun., January 1, 2004; 72(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Leon, K. Wang, and D. M. Engman Myosin Autoimmunity Is Not Essential for Cardiac Inflammation in Acute Chagas' Disease J. Immunol., October 15, 2003; 171(8): 4271 - 4277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Boscardin, S. S. Kinoshita, A. E. Fujimura, and M. M. Rodrigues Immunization with cDNA Expressed by Amastigotes of Trypanosoma cruzi Elicits Protective Immune Response against Experimental Infection Infect. Immun., May 1, 2003; 71(5): 2744 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hoft and C. S. Eickhoff Type 1 Immunity Provides Optimal Protection against Both Mucosal and Systemic Trypanosoma cruzi Challenges Infect. Immun., December 1, 2002; 70(12): 6715 - 6725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Schnapp, C. S. Eickhoff, D. Sizemore, R. Curtiss III, and D. F. Hoft Cruzipain Induces Both Mucosal and Systemic Protection against Trypanosoma cruzi in Mice Infect. Immun., September 1, 2002; 70(9): 5065 - 5074. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
